Elenco degli articoli con argomento «dermatite atopica»
Dermatologia14 ott 2021
Psoriasi e dermatite atopica indicazioni dei dermatologi
Le nuove chances terapeutiche per eliminare le lesioni cutanee e mitigare il prurito, al centro della seconda giornata di lavori del Congresso della Società Italiana di Dermatologia e delle Malattie Sessualmente Trasmesse.
11 ott 2021
Phase 2a randomized clinical trial of dupilumab
Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited
05 ott 2021
Improvement in symptoms of anxiety and depression in patients
Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib
05 ott 2021
Feelings of guilt in parents of children with atopic dermatitis
Feelings of guilt may be associated with illness. Patients may feel responsible for their disease
05 lug 2021
The Role of Type 2 Innate Lymphoid Cells in Allergic Diseases
Allergic diseases are significant diseases that affect many patients worldwide.
07 giu 2021
Once-daily upadacitinib versus placebo in adolescents and adults
Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2.
26 apr 2021
Atopic Dermatitis and Infertility
Given that common pathophysiological factors play a role in atopic dermatitis (AD) and infertility
16 apr 2021
Impact of baricitinib in combination with topical steroids
Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD).
29 mar 2021
Tralokinumab for atopic dermatitis
Tralokinumab for atopic dermatitis
23 mar 2021
Biomarkers in atopic dermatitis
Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations.
16 mar 2021
Note informative per i pazienti - vaccini anti SARS-COV-2 in Italia
Vaccini anti SARS-CoV-2 in uso in Italia
04 mar 2021
A 48-week update
A 48-week update of a multicentre real-life experience of dupilumab in adult patients
24 feb 2021
A Short Cycle of Narrow-Band UVB
Since the best clinical response to dupilumab is achieved after 12-16 weeks
15 feb 2021
Skin Barrier Function in Psoriasis and Atopic Dermatitis
Multiple diagnostic tools are used to evaluate psoriasis and atopic dermatitis (AD) severity, but most of them are based on subjective components.
13 gen 2021
Hidradenitis Suppurativa and Atopic Dermatitis: A Two-Way Association
The co-existence of hidradenitis suppurativa (HS) and atopic dermatitis (AD) had been reported but was not investigated in controlled studies.
24 nov 2020
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
Atopic dermatitis is a common, chronic, immune-mediated disease associated with several comorbidities.
11 nov 2020
Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis
Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one‐year observational cohort study of the first 100 patients treated
20 ott 2020
Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
Dupilumab, an inhibitor of interleukin (IL)‐4/13 activity, is a biological agent approved for the treatment of moderate‐to‐severe atopic dermatitis (AD)
20 ott 2020
Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis
Is exposure to topical calcineurin inhibitors among adult patients with atopic dermatitis associated with increased keratinocyte carcinoma risk?
06 ott 2020
What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice?
A prospective observational study